Clearside Biomedical Announces Advancement Of XIPERE In Asia-Pacific For Suprachoroidal Treatment Of Uveitic Macular Edema As Partner Arctic Vision Completes Enrollment In Phase 3 Clinical Trial In China
Portfolio Pulse from Benzinga Newsdesk
Clearside Biomedical announced that its partner, Arctic Vision, has completed enrollment in a Phase 3 clinical trial in China for XIPERE, a treatment for Uveitic Macular Edema. This marks a significant advancement of XIPERE in the Asia-Pacific region.
October 04, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearside Biomedical's XIPERE treatment for Uveitic Macular Edema is advancing in the Asia-Pacific region as partner Arctic Vision completes Phase 3 trial enrollment in China.
The completion of Phase 3 trial enrollment for XIPERE in China by Clearside Biomedical's partner Arctic Vision indicates progress in the drug's development and potential commercialization. This could positively impact Clearside Biomedical's stock in the short term as it signals potential future revenue from the Asia-Pacific region.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100